Sequential studies on the role of mitoxantrone in the treatment of acute leukaemia.
Mitoxantrone, a synthetic and newly available intercalating agent, was shown to have activity in relapsed or refractory acute leukaemia, which is apparently schedule dependent. A 5-day treatment programme demonstrated impressive activity, with a 50% response rate and 24% complete remissions. Toxicity in these preliminary studies was limited compared to that expected with the anthracycline antibiotics. Mitoxantrone is an active and relatively non-toxic agent which merits further assessment prior to its incorporation in first-line therapy of acute leukaemia.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000880:Anthraquinones / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002478:Cells, Cultured; D002986:Clinical Trials as Topic; D004260:DNA Repair / Q000187:drug effects; D004273:DNA, Neoplasm / Q000037:antagonists & inhibitors; D004353:Drug Evaluation, Preclinical; D006801:Humans; D066298:In Vitro Techniques; D007364:Intercalating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007938:Leukemia / Q000188:drug therapy; D008875:Middle Aged; D008942:Mitoxantrone; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy
D000880:Anthraquinones; D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D007364:Intercalating Agents; D008942:Mitoxantrone